SSRIs and intraocular pressure modifications: Evidence, therapeutic implications and possible mechanisms

CNS Drugs

Volumn 18, Issue 8, 2004, Pages 475-484

  Costagliola, Ciro ^a   Parmeggiani, Francesco ^a   Sebastiani, Adolfo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

5 CARBAMOYLTRYPTAMINE; 5 HYDROXYINDOLEACETIC ACID; 5 HYDROXYTRYPTOPHOL; ADENYLATE CYCLASE; ANTIDEPRESSANT AGENT; BIOGENIC AMINE; CITALOPRAM; CYCLIC AMP; ESCITALOPRAM; EYE DROPS; FLUOXETINE; FLUVOXAMINE; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; SEROTONIN; SEROTONIN 1 RECEPTOR; SEROTONIN 1A AGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2 RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 2C RECEPTOR; SEROTONIN 3 RECEPTOR; SEROTONIN 4 RECEPTOR; SEROTONIN 5 RECEPTOR; SEROTONIN 6 RECEPTOR; SEROTONIN 7 RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; UNINDEXED DRUG; VASOCONSTRICTOR AGENT;

AGITATION; ANXIETY; ASTHENIA; CLINICAL FEATURE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CONSTIPATION; DEPRESSION; DIARRHEA; DISEASE EXACERBATION; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; EYE PAIN; GASTROINTESTINAL DISEASE; GLAUCOMA; HEADACHE; HUMAN; HYPERMETROPIA; INSOMNIA; INTRAOCULAR PRESSURE; MENTAL DISEASE; MYDRIASIS; NAUSEA; NERVOUSNESS; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SOMNOLENCE; SWEATING; TREMOR; VISUAL DISORDER; VISUAL IMPAIRMENT; VOMITING; WITHDRAWAL SYNDROME; XEROSTOMIA;

ANIMALS; ANTIDEPRESSIVE AGENTS; DEPRESSION; EYE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; SEROTONIN; SEROTONIN UPTAKE INHIBITORS;

EID: 3042517006     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200418080-00001     Document Type: Review

References (87)

1. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994; 9 Suppl. 1: 19-26
2. Pacher P, Kohegyi E, Kecskemeti V, et al. Current trends in the development of new antidepressants. Curr Med Chem 2001; 8: 89-100
3. Perry PJ. Pharmacotherapy for major depression with melancholic features: relative efficacy of tricyclic versus selective serotonin reuptake inhibitor antidepressants. J Affect Disord 1996; 39: 1-6
4. Edwards JG, Anderson I. Systematic review and guide to selection of selective serotonin reuptake inhibitors. Drugs 1999; 57: 507-33
5. Preskorn SH. Antidepressant options in primary care. Clin Cornerstone 1999; 1: 31-55
6. Hakanson R. The preclinical observation that escitalopram possesses a faster time to onset of efficacy than citalopram. Pharmacol Toxicol 2002; 90: 3-4
7. Baldessarini RJ. Drugs and the treatment of psychiatric disorders. In: Goodman Gilman A, Hardman JG, Limbird LE, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill Medical Publishing Division, 2001: 447-83
8. Baldessarini RJ. Fifty years of biomedical psychiatry and psychopharmacology in America. In: Menninger R, Nemiah J, editors. American psychiatry after World War II: (1944-1994). Washington: American Psychiatric Press, 2000: 369-410
9. Baldwin D, Johnson RN. Tolerability and safety of citalopram. Rev Contemp Pharmacother 1995; 6: 315-25
10. Cooper GL. The safety of fluoxetine: an update. BrJ Psychiatry 1988; 15 Suppl. 3: 77-86
11. Wagner W, Zaborny BA, Gray TE. Fluvoxamine: a review of its safety profile in world-wide studies. Int Clin Psychopharmacol 1994; 9: 223-7
12. Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992; 53 Suppl. 2: 61-6
13. Doogan DP. Toleration and safety of sertraline: experience worldwide. Int Clin Psychopharmacol 1991; 6 Suppl. 2: 47-56
14. Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs 2003; 17: 343-62
15. Preskorn SH. Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline and venlafaxine. J Clin Psychiatry 1995; 56 Suppl. 6: 12-21
16. Trindade E, Menon D, Topfer LA, et al. Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic amidepressams: a meta-analysis. CMAJ 1998; 159: 1245-52
17. Ahmad S. Fluoxetine and glaucoma [letter]. DICP 1991; 25: 436
18. Kirwan JF, Subak-Sharpe I, Teimory M. Bilateral acute angle closure glaucoma after administration of paroxetine [letter]. Br J Ophthalmol 1997; 81: 252
19. Lewis CF, DeQuardo JR, DuBose C, et al. Acute angle-closure glaucoma and paroxetine. J Clin Psychiatry 1997; 58: 123-4
20. Eke T, Bates AK. Acute angle closure glaucoma associated with paroxetine [letter]. BMJ 1997; 314: 1387
21. Bennett HG, Wyllie AM. Paroxetine and acute angle-closure glaucoma. Eye 1999; 13: 691-2
22. Browning AC, Reck AC, Chisholm IH, et al. Acute angle closure glaucoma presenting in a young patient after administration of paroxetine. Eye 2000; 14: 406-8
23. Jimenez-Jimenez FJ, Orti-Pareja M, Zurdo JM. Aggravation of glaucoma with fluvoxamine. Ann Pharmacother 2001; 35: 1565-6
24. Adverse Drug Reactions Advisory Committee (ADRAC). SSRIs and increased intraocular pressure. Australian Adverse Drugs Reaction Bulletin 2001; 20/1: 3
25. Costagliola C, Mastropasqua L, Steardo L, et al. Fluoxetine oral administration increases intraocular pressure [letter to the editor]. Br J Ophthalmol 1996; 80: 678
26. Murray CJ, Lopez AD. Evidence-based health policy-lessons from the Global Burden of Disease Study. Science 1996; 274: 740-3
27. Lopez AD, Murray CJ. The global burden of disease, 1990-2020. Nat Med 1998; 4: 1241-3
28. Murray CJ, Lopez AD. On the comparable quantification of health risks: lessons from the Global Burden of Disease Study. Epidemiology 1999; 10: 594-605
29. Blazer DG, Kessler RC, McGonagle KA, et al. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. Am J Psychiatry 1994; 151: 979-86
30. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994; 51: 8-19
31. Greenblatt DJ, von Moltke LL, Harmatz JS, et al. Human cytochromes and some newer antidepressants: kinetics, metabolism, and drug interactions. J Clin Psychopharmacol 1999; 19 Suppl. 1: 23S-35S
32. Cadieux RJ. Antidepressant drug interactions in the elderly: understanding the P-450 system is half the battle in reducing risks. Postgrad Med 1999; 106: 231-2, 237-40, 245-9
33. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32 Suppl. 1: 1-21
34. Alfaro CL, Lam YW, Simpson J, et al. CYP2D6 status of extensive metabolizers after multiple-dose fluoxetine, fluvoxamine, paroxetine, or sertraline. J Clin Psychopharmacol 1999; 19: 155-63
35. von Bahr C, Ursing C, Yasui N, et al. Fluvoxamine but not citalopram increases serum melatonin in healthy subjects: an indication that cytochrome P450 CYP1A2 and CYP2C19 hydroxylate melatonin. Eur J Clin Pharmacol 2000; 56: 123-7
36. von Moltke LL, Greenblatt DJ, Giancarlo GM, et al. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos 2001; 29: 1102-9
37. Liston HL, DeVane CL, Boulton DW, et al. Differential time course of cytochrome P450 2D6 enzyme inhibition by fluoxetine, sertraline, and paroxetine in healthy volunteers. J Clin Psychopharmacol 2002; 22; 169-73
38. Settle Jr EC. Antidepressant drugs: disturbing and potentially dangerous adverse effects. J Clin Psychiatry 1998; 59 Suppl. 16: 25-30
39. Lohmann PL, Rao ML, Ludwig M, et al. Influence of CYP2D6 genotype and medication on the sparteine metabolic ratio of psychiatric patients. Eur J Clin Pharmacol 2001; 57: 289-95
40. Steimer W, Muller B, Leucht S, et al. Pharmacogenetics: a new diagnostic tool in the management of antidepressive drug therapy. Clin Chim Acta 2001; 308: 33-41
41. Black K, Shea C, Dursun S, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: proposed diagnostic criteria. J Psychiatry Neurosci 2000; 25: 255-61
42. Davson H. Physiology of the aqueous humour. In: Davson H, editor. Physiology of the eye. London: Churchill Livingstone, 1980: 9-82
43. Morrison JC, Freddo TF. Anatomy, microcirculation, and ultrastructure of the ciliary body. In: Ritch R, Shields MB, Krupin T, editors. The glaucomas: clinical science. Vol. 1. 2nd ed. St Louis: Mosbly-Year Book Inc, 1996: 125-38
44. Krupin T, Civan MM. Physiologic basis of aqueous humour formation. In: Ritch R, Shields MB, Krupin T, editors. The glaucomas: clinical science. Vol. 1. 2nd ed. St Louis: Mosbly-Year Book Inc, 1996: 251-80
45. Bonomi L, Marchini G, Marraffa M, et al. Prevalence of glaucoma and intraocular pressure distribution in a defined population. The Egna-Neumarkt Study. Ophthalmology 1998; 105: 209-15
46. Boles Carenini B, Brogliatti B. Intraocular pressure as a risk factor in glaucoma. In: Bucci MG, editor. Glaucoma: decision making in therapy. Milan: Springer-Verlag, 1996: 9-14
47. Flammer J, Orgül S, Costa VP, et al. The impact of ocular blood flow in glaucoma. Prog Retin Eye Res 2002; 21: 359-93
48. European Glaucoma Society. Terminology and guidelines for glaucoma. Savona: Editrice DOGMA® S.r.l., 1998
49. Shields MB, Ritch R, Krupin T. Classifications of the glaucomas. In: Ritch R, Shields MB, Krupin T, editors. The glaucomas: clinical science. Vol. 2. 2nd ed. St Louis: Mosbly-Year Book Inc, 1996: 717-25
50. Bonomi L, Marchini G, Marraffa M, et al. Epidemiology of angle-closure glaucoma: prevalence, clinical types, and association with peripheral anterior chamber depth in the Egna-Neumarket Glaucoma Study. Ophthalmology 2000; 107: 998-1003
51. Rapport MM, Green AA, Page IH. Serum vasoconstrictor (serotonin) IV: isolation and characterization. J Biol Chem 1948; 176: 1243-51
52. Sanders-Bush E, Mayer SE. 5-hydroxytryptamine (serotonin): receptor, agonists and antagonists. In: Goodman Gilman A, Hardman JG, Limbird LE, editors. Goodman & Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill Medical Publishing Division, 2001: 269-90
53. Glennon RA, Dukat M. Serotonin receptors and drugs affecting serotonergic neurotransmission. In: Williams DA, Lemke T, editors. Foye's textbook of medical chemistry. Baltimore: Williams and Wilkins Inc, 2002: 315-37
54. Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002; 71: 533-54
55. Hoyer D, Clarke DE, Fozard JR, et al. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev 1994; 46: 157-204
56. Zifa E, Fillion G. 5-hydroxytryptamine receptors. Pharmacol Rev 1992; 44: 401-58
57. Boess FG, Martin IL. Molecular biology of 5-HT receptors. Neuropharmacology 1994; 33: 275-317
58. Osborne NN, Meyer-Bothling U, Barnett NL. Serotonin receptors in the eye. In: Andersen DR, Drance SM, editors. Encounters in glaucoma research 1: receptor biology and glaucoma. Milan: Fogliazza Editore, 1994: 331-64
59. Ullmer C, Schmuck K, Kalkman HO, et al. Expression of serotonin receptor mRNAs in blood vessels. FEBS Lett 1995; 370: 215-21
60. Somer E, Snyderman NL. Food and mood: the complete guide to eating well and feeling your best. 2nd ed. New York: Henry Holt & Company Inc, 1999
61. Klyce SD, Palkama KA, Harkonen M, et al. Neural serotonin stimulates chloride transport in rabbit corneal epithelium. Invest Ophthalmol Vis Sci 1982; 23: 181-92
62. Uusitalo H, Lehtosalo J, Laakso J, et al. Immunocytochemical and biochemical evidence for 5-hydroxytryptamine containing nerves in the anterior part of the eye. Exp Eye Res 1982; 35: 671-5
63. Tobin AB, Unger W, Osborne NN. Evidence for the presence of serotonergic neurons and receptors in the iris-ciliary body complex of the rabbit. J Neurosci 1988; 8: 3713-21
64. 1A and 5-hydroxytryptamine? receptors in rabbit ocular and brain tissues. Neuroscience 1998; 87: 675-89
65. Ehinger B, Holmgren I. Electron microscopy of the indoleamine accumulating neurons in the rabbit retina. Cell Tissue Res 1979; 197: 175-94
66. Osborne NN. The occurrence of serotonergic nerves in the bovine cornea. Neurosci Lett 1983 Jan 31; 35: 15-8
67. Osborne NN. Indoleamines in the eye with special reference to the serotonergic neurones of the retina. In: Osborne NN, Chader J, editors. Progress in retinal research. Vol. 3. Oxford: Pergamon Press, 1984: 61-103
68. Osborne NN, Tobin AB. Serotonin-accumulating cells in the iris-ciliary body and cornea of various species. Exp Eye Res 1987; 44: 731-45
69. Martin XD, Malina HZ, Brennan MC, et al. The ciliary body: the third organs found to synthesize indoleamines in humans. Eur J Ophthalmol 1992; 2: 67-72
70. 1A receptors have similar functions in the control of intraocular pressure in the rabbit? Ophthalmologica 1996; 210: 308-14
71. 1) receptors negatively coupled to adenylate cyclase in rabbit and human iris-ciliary processes. Exp Eye Res 1993; 57: 209-16
72. Tobin AB, Osborne NN. Evidence for the presence of serotonin receptors negatively coupled to adenylate cyclase in the rabbit iris-ciliary body. J Neurochem 1989; 53: 686-91
73. Mallorga P, Sugrue MF. Characterization of serotonin receptors in the iris+ciliary body of the albino rabbits. Curr Eye Res 1987; 6: 527-32
74. Ritch R, Lowe RF. Angle-closure glaucoma: clinical types. In: Ritch R, Shields MB, Krupin T, editors. The glaucomas: clinical science. Vol. 2. 2nd ed. St. Louis: Mosbly-Year Book Inc, 1996: 821-40
75. (1A) receptor agonist 8-OH-DPAT lowers intraocular pressure in normotensive NZW rabbits. Exp Eye Res 1999; 69: 587-93
76. 1-agonist 5-CT intraocular pressure in rabbits. Invest Ophthalmol Vis Sci 1993; 34: 3035-42
77. 1A agonists: potential use in glaucoma: evidence from animal studies. Eye 2000; 14: 454-63
78. Tian RX, Kimura S, Kondou N, et al. DOI, a 5-HT2 receptor agonist, induces renal vasodilation via nitric oxide in anesthetized dogs. Eur J Pharmacol 2002; 437: 79-84
79. Costagliola C, Mastropasqua L, Capone D, et al. Effect of fluoxetine on intraocular pressure in the rabbit. Exp Eye Res 2000; 70: 551-5
80. Costagliola C, Iuliano G, Rinaldi M, et al. Effect of topical ketanserin administration on intraocular pressure. Br J Ophthalmol 1993; 77: 344-8
81. Goldmann H. On pseudofacility. Bibl Ophthalmol 1968; 76: 1-14
82. Bill A, Barany EH. Gross facility, facility of conventional routes and pseudofacility of aqueous humour outflow in the cynomolgus monkey. Arch Ophthalmol 1966; 75: 665-73
83. Lutjen-Drecoll E, Shimizu T, Rohrbach M, et al. Quantitative analysis of 'plaque material' in the inner- and outer wall of Schlemm' s canal in normal- and glaucomatous eyes. Exp Eye Res 1986; 42: 443-55
84. Beasley Jr CM, Koke SC, Nilsson ME, et al. Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis. Clin Ther 2000; 22: 1319-30
85. Thompson C, Peveler RC, Stephenson D, et al. Compliance with antidepressant medication in the treatment of major depressive disorder in primary care: a randomized comparison of fluoxetine and a tricyclic antidepressant. Am J Psychiatry 2000; 157: 338-43
86. Palmberg P. Gonioscopy. In: Ritch R, Shields MB, Krupin T, editors. The glaucomas: clinical science. Vol. 1. 2nd ed. St Louis: Mosbly-Year Book Inc, 1996: 455-69
87. Lieberman E, Stoudemire A. Use of tricyclic antidepressants in patients with glaucoma: assessment and appropriate precautions. Psychosomatics 1987; 28: 145-8